About IgA Nephropathy
IgA Nephropathy is the most prevalent primary glomerulonephritis globally, caused by mesangial deposition of poorly galactosylated polymeric IgA1 and subsequent complement activation and immune complex formation, leading to glomerular inflammation and progressive kidney injury. Clinical presentation ranges from asymptomatic hematuria detected incidentally to nephrotic syndrome and rapidly progressive glomerulonephritis, with approximately 30-40% of patients reaching end-stage kidney disease within 20-30 years. The expanding pipeline of targeted therapies — including endothelin-angiotensin system inhibitors, BAFF/APRIL inhibitors, complement pathway blockers, and sparsentan — has made IgA nephropathy one of the most actively trialed rare kidney diseases.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to IgA Nephropathy trials.
Kidney biopsy with Oxford classification (MEST-C score) is required by virtually all trials; ensure pathology report includes mesangial IgA deposit confirmation on immunofluorescence
Proteinuria threshold (commonly >1 g/day or >0.5 g/g urine protein:creatinine ratio) and eGFR range (often 30-90 mL/min/1.73m2) are the primary eligibility gatekeepers; provide 24-hour urine or spot ratio from last 3 months
Maximum-tolerated RAS blockade is a prerequisite for most trials; document ACE inhibitor or ARB dose and duration along with current blood pressure readings
Patient Resources
Find recruiting IgA Nephropathy trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for IgA Nephropathy. Updated daily.